ASAAP-plus Clinical evaluation of AntimalarialS tri-therapy with AtovAquone-Proguanil for treatment of uncomplicated malaria in African children
- Coordinator
- Bernhard-Nocht-Institut Fuer Tropenmedizin, Germany
- Runs
- 1 January 2024 to 31 December 2026
- Status
- Running
- EU funding
- €1.5m
- Total cost
- €1.5m
- Partners
- 7 organisations in 7 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101145769
What the project is doing
In the project's own words, from its summary on CORDIS.
Susceptibility to Artemisinin-based combination therapies (ACTs) currently remains high among the African Plasmodium falciparum population, but resistant mutant has been detected recently. To mitigate the risk of resistance leading to a dramatic increase in malaria related mortality, more efficient ACTs need to be urgently explored for quick deployment in Africa. Artemether-lumefantrine (AL) is widely used and shows high efficacy and favourable safety in Africa but needs to be protected to increase its useful lifespan.
Atovaquone-proguanil (AP) is highly efficacious, safe and resistant parasites are not circulating in any endemic area. AP targets multiple parasite stages -liver and blood in human host, and mosquito- through an independent mode of action, limiting the risk of cross-resistance with current ACTs. The aim of the project is to assess the efficacy of a triple-therapy associating artemether-lumefantrine (AL) and atovaquone-proguanil (AP) for the treatment of uncomplicated P. falciparum malaria in African children in a non-inferiority comparator-controlled trial.
A phase III clinical trial will be conducted to compare safety and cure rate of a 3-day treatment course with AL+AP versus AL in 1,664 consenting 6 to 70 months children with uncomplicated malaria from Benin, Gabon, Ghana and Mali. The main outcome will be cure rate at day-42, excluding reinfections. Antimalarial pharmacokinetic parameters and post-treatment prophylactic efficacy will be estimated for the two treatments and compared.
Sub-studies will look at transmission-blocking efficacy through membrane-feeding assays and gametocyte dynamics, drug resistance selection. By proofing that AL+AP has safety and cure rate similar to AL, this project will lead to important public health-level benefits by provision of a first candidate regimen to be deployed when ACT resistance spreads throughout Africa and by decreasing human to mosquito transmission.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Bernhard-Nocht-Institut Fuer Tropenmedizin | Hamburg | Germany | Coordinator |
| Institut Des Sciences Et Techniques | Bobo Dioulasso | Burkina Faso | Participant |
| Institut De Recherche Clinique Du Benin (ircb) | Cotonou | BJ | Participant |
| Institut De Recherche Pour Le Developpement | Marseille | France | Participant |
| Centre de Recherches Medicales de Lambaréné | Lambaréné | GA | Participant |
| Kwame Nkrumah University of Science and Technology Kumasi | Kumasi | Ghana | Participant |
| Universite Des Sciences Des Techniques Et Des Technologies De Bamako | Bamako | ML | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI